Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia

Jad Othman(The University of Sydney), Robin Gasiorowski(The University of Sydney), James Hilger, Leo Lin(University of California San Diego), Judith Trotman(The University of Sydney), Emma Verner(Concord Repatriation General Hospital), Jane Huang(University of Southern California), Constantine S. Tam(The Alfred Hospital)
Haematologica
February 8, 2018
10.3324/haematol.2017.186817
Cited by 12

Related Papers

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
|American Journal of Hematology|2019|472